We’re hosting a get together to network and have Dr. Jake Hutchins MD, Executive Medical Director at M Health Ambulatory Surgery Center, discuss the advancements made within […]
We’re hosting a get together to network and have Dr. Jake Hutchins MD, Executive Medical Director at M Health Ambulatory Surgery Center, discuss the advancements made within […]
I hope this letter finds you off to a great 2019. To receive timely information on your Company, please check back here or head on over to […]
Casual conversation, drinks, appetizers & NCAA Sweet 16 Hoops Thursday, March 28th | 5-?? PM D’Arcy’s Tavern – Bradley Beach, NJ* *Reservation Required RSVP: https://www.eventbrite.com/e/investing-in-biotech-investors-for-non-opiate-pain-solutions-dinner-tickets-58183002928
Join Us for Lunch & an Investment Presentation Monday, April 8 or Tuesday, April 9 11:30 – 2:00 each day Naples Beach Hotel & Golf Club* *Reservation […]
The government shutdown in December and January has caused a tremendous backlog of quarterly and year-end filings for review at the SEC. Accordingly, our updated RegA+ Offering […]
I hope this note finds you off to a great 2019. We are pleased to announce that InSitu Biologics Stock Offering will again open on Wednesday, January […]
WOODBURY, Minn., Dec. 4, 2018 /Press Release/ — InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGel™, has received over $2 million in […]
Our Tier 3 of 30,000 shares is nearly full and we will pause our Stock Offering on Tuesday, November 27, 2018. At that time we plan on […]
Quick update for shareholders and prospective investors. We closed our Tier 2 $6.85 level with 43,126 shares sold. The SEC approved our Tier 3 with another share […]
This is Jim Segermark, CEO and Co-Founder of InSitu Biologics. Quick note to share our progress and upcoming events with you. If you live, or happen to […]